ASTROTECH Corp ASTC
We are commercializing the Astrotech Mass Spectrometer Technology™ platform ("AMS Technology") through application specific, wholly owned subsidiaries.
Our mission encompasses the advancement of both mass spectrometry and gas chromatography, two powerful analytical techniques that together enable precise detection and identification of chemical compounds across a wide range of high-demand environments. We aim to expand access to mass spectrometry by simplifying the complexity of operating these devices within real-time testing environments such as airports, border checkpoints, cargo hubs, infrastructure security, correctional facilities, military bases, law enforcement centers, and industrial locations. We are introducing our new line of products that are ultra-portable, on-site, rugged environmental testing instruments, featuring our proprietary ATi Mass Spectrometer Technology ("MS") and ATi Gas Chromatography Column ("GC") to achieve our mission through simplifying the user interface, ruggedizing the critical components to endure MS/GC field work, and enabling multiple configurations for sample intake options. The Astrotech Mass Spectrometer Technology™ and ATi Gas Chromatograph Column (GC) platforms achieve our mission through simplifying the user interface, automating the complicated calibration process, ruggedizing the critical components to endure MS/GC field work, and enabling multiple configurations for sample intake options.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.7M | $750.0K | $869.0K | $334.0K | $488.0K | $127.0K | $86.0K | $2.3M | $2.7M |
| Cost of revenue | $574.0K | $913.0K | $444.0K | $677.0K | $298.0K | $449.0K | $90.0K | $36.0K | $1.3M | $2.3M |
| Gross profit | $475.0K | $751.0K | $306.0K | $192.0K | $36.0K | $39.0K | $37.0K | $50.0K | $1.0M | $339.0K |
| R&D | $8.1M | $6.8M | $5.6M | $2.8M | $2.7M | $3.4M | $3.6M | $6.1M | $5.6M | $6.5M |
| SG&A | $7.1M | $7.2M | $5.8M | $6.0M | $4.7M | $4.7M | $4.9M | $5.6M | $7.5M | $7.7M |
| Total operating expenses | $15.2M | $14.0M | $11.4M | $8.8M | $7.9M | $8.2M | $8.5M | $13.4M | $13.1M | $14.2M |
| Operating income | -$14.7M | -$13.3M | -$11.1M | -$8.6M | -$7.9M | -$8.1M | -$8.4M | -$13.3M | -$12.1M | -$13.8M |
| Pre-tax income | -$13.8M | -$11.7M | -$9.6M | -$8.3M | -$7.6M | -$8.3M | -$8.4M | -$13.3M | -$11.8M | -$13.5M |
| Income tax | $2.0K | $2.0K | $0 | $0 | $0 | $0 | $858.0K | $0 | $2.0K | $25.0K |
| Net income | -$13.8M | -$11.7M | -$9.6M | -$8.3M | -$7.6M | -$8.3M | -$7.5M | -$13.3M | -$11.6M | -$13.1M |
| EPS, basic | -8.32 | -7.12 | -5.95 | -5.24 | -0.35 | — | — | — | — | — |
| EPS, diluted | — | — | — | — | -0.35 | -1.31 | -1.53 | -3.26 | -2.84 | -0.64 |
| Shares, diluted (wtd. avg.) | 1.7M | 1.6M | 1.6M | 1.6M | 22.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | $35.9M | $3.3M | $1.6M | $552.0K | $2.2M | $4.4M |
| Short-term investments | $15.1M | $21.5M | $27.9M | $26.2M | $27.4M | $0 | — | $3.6M | $10.9M | $17.1M |
| Receivables | $485.0K | $77.0K | $225.0K | $56.0K | $5.0K | $101.0K | $3.0K | $12.0K | $146.0K | $156.0K |
| Inventory | — | — | — | — | — | — | — | $7.0K | $166.0K | — |
| Total current assets | $22.0M | $34.7M | $44.7M | $55.0M | $65.1M | $4.7M | $2.7M | $4.3M | $13.7M | $22.9M |
| Property, plant and equipment | $2.4M | $2.8M | $2.7M | $1.1M | $263.0K | $99.0K | $469.0K | $733.0K | $3.2M | $3.4M |
| Other intangibles | $48.0K | $0 | — | — | — | — | — | — | — | — |
| Total assets | $27.0M | $37.6M | $47.7M | $56.2M | $65.6M | $5.9M | $3.7M | $5.1M | $18.8M | $30.5M |
| Accounts payable | $1.1M | $373.0K | $546.0K | $169.0K | $396.0K | $239.0K | $160.0K | $112.0K | $259.0K | $237.0K |
| Total current liabilities | $2.5M | $2.5M | $2.7M | $2.7M | $4.2M | $4.3M | $838.0K | $960.0K | $1.8M | $1.8M |
| Long-term debt | — | — | — | — | — | — | — | $0 | $0 | $0 |
| Total liabilities | $4.9M | $2.8M | $3.0M | $3.0M | $4.4M | $5.3M | $984.0K | $1.1M | $2.1M | $1.9M |
| Retained earnings | -$250.9M | -$237.0M | -$225.4M | -$215.7M | -$207.4M | -$199.8M | -$191.7M | -$184.2M | -$170.9M | -$159.1M |
| Total equity | $22.1M | $34.8M | $44.7M | $53.2M | $61.2M | $625.0K | $2.7M | $4.0M | $16.8M | $28.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.0M | -$9.7M | -$7.6M | -$6.8M | -$7.4M | -$6.9M | -$8.5M | -$10.8M | -$8.8M | -$13.3M |
| Depreciation and amortisation | $962.0K | $731.0K | $366.0K | $148.0K | $203.0K | $533.0K | $268.0K | $749.0K | $711.0K | $600.0K |
| Stock-based compensation | $830.0K | $1.5M | $1.5M | $1.5M | $626.0K | $348.0K | $305.0K | $450.0K | $1.1M | $551.0K |
| Capital expenditure | $833.0K | $579.0K | $1.8M | $596.0K | $211.0K | $0 | $0 | $19.0K | $499.0K | $809.0K |
| Investing cash flow | $5.8M | $6.1M | -$3.8M | -$596.0K | -$27.6M | $0 | $3.6M | $9.2M | $7.9M | $15.5M |
| Financing cash flow | -$185.0K | -$181.0K | -$776.0K | -$2.1M | $67.6M | $8.7M | $5.9M | -$7.0K | -$1.3M | -$140.0K |
| Buybacks | $0 | $0 | $119.0K | $0 | — | — | $1.0K | $7.0K | $1.3M | $156.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-25-029909.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7M | $2.3M | $86.0K | $127.0K | $488.0K | $334.0K | $869.0K | $750.0K | $1.7M | $1.0M |
| Gross profit | $339.0K | $1.0M | $50.0K | $37.0K | $39.0K | $36.0K | $192.0K | $306.0K | $751.0K | $475.0K |
| Net income | -$13.1M | -$11.6M | -$13.3M | -$7.5M | -$8.3M | -$7.6M | -$8.3M | -$9.6M | -$11.7M | -$13.8M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Results announced Item 2.02
- Material agreement signed Item 1.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $48.79B | 37.9x | 6.7% |
| WAT | WATERS CORP /DE/ | $44.57B | 42.2x | 7.0% |
| ILMN | ILLUMINA, INC. | $40.68B | 49.4x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $33.47B | 39.7x | 4.0% |
| RVTY | REVVITY, INC. | $17.72B | 76.7x | 3.7% |
| AVTR | Avantor, Inc. | $11.80B | — | -3.4% |
| BIO | BIO-RAD LABORATORIES, INC. | $9.89B | 13.3x | 0.7% |
| TXG | 10x Genomics, Inc. | $9.30B | — | 5.2% |